Found: 8
Select item for more details and to access through your institution.
Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study.
- Published in:
- Frontiers in Immunology, 2023, v. 13, p. 01, doi. 10.3389/fimmu.2022.1074044
- By:
- Publication type:
- Article
Tumor Necrosis Factor Inhibitor Monotherapy Versus Combination Therapy for the Treatment of Psoriatic Arthritis: Combined Analysis of European Biologics Databases.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence.
- Published in:
- 2018
- By:
- Publication type:
- journal article
A Peripheral Blood Signature of Increased Th1 and Myeloid Cells Combined with Serum Inflammatory Mediators Is Associated with Response to Abatacept in Rheumatoid Arthritis Patients.
- Published in:
- Cells (2073-4409), 2023, v. 12, n. 24, p. 2808, doi. 10.3390/cells12242808
- By:
- Publication type:
- Article
Rheumatoid arthritis patients on persistent moderate disease activity on biologics have adverse 5-year outcome compared to persistent low-remission status and represent a heterogeneous group.
- Published in:
- Arthritis Research & Therapy, 2020, v. 22, n. 1, p. N.PAG, doi. 10.1186/s13075-020-02313-w
- By:
- Publication type:
- Article
Distinct long-term disease activity trajectories differentiate early on treatment with etanercept in both rheumatoid arthritis and spondylarthritis patients: a prospective cohort study.
- Published in:
- Rheumatology International, 2024, v. 44, n. 2, p. 249, doi. 10.1007/s00296-023-05455-7
- By:
- Publication type:
- Article
Baseline IgG-Fc N-glycosylation profile is associated with long-term outcome in a cohort of early inflammatory arthritis patients.
- Published in:
- Arthritis Research & Therapy, 2022, v. 24, n. 1, p. 1, doi. 10.1186/s13075-022-02897-5
- By:
- Publication type:
- Article
Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study.
- Published in:
- Arthritis Research & Therapy, 2022, v. 24, n. 1, p. 1, doi. 10.1186/s13075-022-02826-6
- By:
- Publication type:
- Article